Stock Events

Stock Events

Vicore Pharma AB 

$10.40
11
+$0.39+3.9%Friday 21:00
+$0.46+4.42%Friday 21:00After hours

Statistics

Day High
10.35
Day Low
10.35
52W High
17.8
52W Low
7.88
Volume
52
Avg. Volume
-
Mkt Cap
292.91M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q1 2026
Q2 2026
Next
-0.05
-0.05
-0.04
-0.04
Expected EPS
-0.05099375
Actual EPS
N/A

Financials

-12,563.6%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
399,892.17Revenue
-50.24MNet Income

Analyst Ratings

$25.00Average Price Target
The highest estimate is ⁦25.00⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VCRE. It's not an investment recommendation.
Svenska Handelsbanken AB (publ)
4
SHB-A.ST
Aker BP ASA
3
AKRBP.OL
Atlas Copco AB
3
ATCO-B.ST
Lundin Mining
3
LUMI.ST

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals is involved in developing therapies for treating cystic fibrosis and other serious diseases, overlapping with Vicore's focus on rare lung disorders.
Incyte
INCY
Mkt Cap24.54B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including treatments for pulmonary diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including rare genetic disorders that overlap with Vicore's market.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is known for its development of treatments for serious medical conditions, including respiratory and inflammatory diseases, competing with Vicore's product pipeline.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences' involvement in pulmonary and fibrotic diseases places it in direct competition with Vicore's therapeutic areas.
Novo Nordisk
NVO
Mkt Cap176.43B
Novo Nordisk is engaged in the discovery and development of biological therapies, including areas that could compete with Vicore's interest in rare diseases.

About

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
Show More
CEO
Ahmed S. Mousa
Employees
40
Country
Sweden
ISIN
US92581R1041
WKN
000A42DDX

Listings

XNAS
US
VCRE
STU
DE
6Y4.STU
ST
SE
VICO-BTA.ST
F
DE
6Y40.F

0 Comments

Share your thoughts

FAQs

What is Vicore Pharma AB stock price today?▼
The current price of VCRE is $10.40 USD — it has increased by +3.9% in the past 24 hours. Watch Vicore Pharma AB stock price performance more closely on the chart.
What is Vicore Pharma AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Vicore Pharma AB stocks are traded under the ticker VCRE.
What is Vicore Pharma AB market cap?▼
Today Vicore Pharma AB has the market capitalization of 292.91M
When is the next Vicore Pharma AB earnings date?▼
Vicore Pharma AB is going to release the next earnings report on February 25, 2027.
What is Vicore Pharma AB revenue for the last year?▼
Vicore Pharma AB revenue for the last year amounts to 399,892.17 USD.
What is Vicore Pharma AB net income for the last year?▼
VCRE net income for the last year is -50.24M USD.
How many employees does Vicore Pharma AB have?▼
As of November 8, 2026, the company has 40 employees.
In which sector is Vicore Pharma AB located?▼
Vicore Pharma AB operates in the Health & Wellness sector.
When did Vicore Pharma AB complete a stock split?▼
Vicore Pharma AB has not had any recent stock splits.
Where is Vicore Pharma AB headquartered?▼
Vicore Pharma AB is headquartered in Stockholm, Sweden.